All Oncology News

The EMA’s CHMP has issued a positive opinion supporting the approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

UF-Kure19, a rapidly manufactured CAR T-cell therapy, generated an 80% complete response rate in relapsed/refractory non-Hodgkin lymphoma.

Experts break down emerging data for the use of quadruplet regimens in newly diagnosed multiple myeloma.

A phase 2 study demonstrated that TAK-007 had a favorable safety profile with early efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma.

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Austin D. Williams, MD, MSEd, FACS, was recently named a Presidential Scholar by the Society of Surgical Oncology.

The CHMP has recommended approval for durvalumab in limited-stage small cell lung cancer following platinum-based chemoradiation.

The FDA accepted a BLA seeking the approval of the pertuzumab biosimilar HLX11 for HER2-positive breast cancer.

Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

The FDA has approved a companion diagnostic for trastuzumab deruxtecan in hormone receptor–positive, HER2-ultralow metastatic breast cancer.

Coauthor of the Lancet Breast Cancer Commission report, Reshma Jagsi, MD, DPhil, details the 6 themes of the evidence-based plan aimed to address challenges in the field.

The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.

Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC.

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

A retrospective analysis showed a high proportion of endometrial cancer samples expressed FRα or B7-H4.

Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.

R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.

Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.

Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.

Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.

OS outcomes with lenvatinib plus pembrolizumab were prolonged in patients with PPP2R1A-mutated vs wild-type high-risk endometrial cancer.

The EMA’s CHMP has adopted a positive opinion regarding frontline nivolumab plus ipilimumab in unresectable or advanced hepatocellular carcinoma.

China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.

The EMA’s CHMP has recommended the approval of liso-cel for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.